Opinion|Videos|June 26, 2024
Efficacy End Points For PNH Treatment
Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe the significance of the different efficacy end points explored for paroxysmal nocturnal hemoglobinuria treatments (eg, lactate dehydrogenase levels, hemoglobin concentrations, absolute reticulocyte count (ARC) levels, transfusion avoidance, Functional Assessment of Chronic Illness Therapy–Fatigue).
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
2
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
3
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
4
Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL
5
